Nuvectis Pharma, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Nuvectis Pharma, Inc. (NVCT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$160.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-11-08
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $1.37M, a 6.05% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was $276.00K, a 6.15% increase year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was -$1.80M, a 432.47% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-12-31 was $1.88M, a 71.27% increase year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $4.14M, a 161.20% increase from fiscal 2021.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $1.58M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.64M derived: sum of 2 quarters · filed 2023-11-08 | -$160.00K 10-Q · filed 2023-11-08 | $1.72M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.53M 10-Q · filed 2023-08-09 | $358.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.81M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-03-31 | -$1.80M 10-Q · filed 2023-05-10 | $82.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.54M derived: sum of 3 quarters · filed 2023-11-08 | $1.80M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $3.34M derived: sum of 2 quarters · filed 2023-11-08 | $3.60M derived: sum of 3 quarters · filed 2023-11-08 | $4.14M 10-K · filed 2023-03-08 |
| 2022-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.71M derived: sum of 2 quarters · filed 2023-11-08 | $2.26M 10-Q · filed 2023-11-08 | $3.36M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $260.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $802.00K 10-Q · filed 2023-08-09 | $1.90M derived: sum of 3 quarters · filed 2023-08-09 | $2.01M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $542.00K 10-Q · filed 2023-05-10 | $1.64M derived: sum of 2 quarters · filed 2023-05-10 | $1.75M derived: sum of 3 quarters · filed 2023-05-10 | $2.10M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.21M derived: sum of 2 quarters · filed 2023-03-08 | $1.56M derived: sum of 3 quarters · filed 2023-03-08 | $1.58M 10-K · filed 2023-03-08 |
| 2021-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $462.00K derived: sum of 2 quarters · filed 2022-11-08 | $485.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $379.00K 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $23.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |